Archives: MFN News Items

Sex av tio sjuksköterskor varnar för undermålig läkemedelshantering

Läkemedelshanteringen på Sveriges äldreboenden brister på flera områden och är inte patientsäker. Arbetet delegeras till vård- och omsorgspersonal som saknar behörighet och många patienter får skadlig medicin. Det visar en ny undersökning från Ivo.

Inspektionen för vård och omsorg (Ivo) har granskat situationen på Sveriges särskilda boenden för äldre (Säbo) och konstaterar att det finns brister i samtliga granskade 283 kommuner. Ett bristområde är läkemedelshanteringen där var fjärde sjuksköterska uppger att de delegerar iordningställande av läkemedel i dosett till vård- och omsorgspersonal, som ofta saknar den kompetens som krävs och ofta har bristande språkkunskaper. 58 procent av de tillfrågade sjuksköterskorna ser säkerhetsrisker vid sådan delegering av läkemedelshantering.
– Brister i läkemedelshantering har länge varit ett stort problem, särskilt bland våra äldre multisjuka. Det är en stor säkerhetsrisk som leder till allvarliga konsekvenser, inte bara för de drabbade och deras anhöriga utan även för samhället i stort, säger Anders Segerström, vd iZafe Group.

Stor kostnad
Multisjuka äldre använder i snitt närmare tio läkemedel per dag och står för en stor del av akutintagen. Enligt Läkemedelsrådet är fyra av tio akutbesök i Sverige orsakat av felaktig läkemedelsbehandling. Det innebär en kostnad för samhället på 20 miljarder kronor per år. Ivos granskning visar också att var femte patient har läkemedel som bör undvikas bland äldre.
– Det handlar inte bara om allt mänskligt lidande och ekonomiska konsekvenser som orsakas av felaktig läkemedelshantering utan det har också arbetsmiljöpåverkande konsekvenser för många sjuksköterskor. Utöver deras redan pressade arbetssituation tvingas de ofta oroa sig för om medicineringen skett på ett korrekt sett, säger Anders Segerström.

Kontakter

Anders Segerström, Verkställande Direktör
Mail:
Mobilnummer: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-post:
www.izafe.se/investor-relations/

Om iZafe Group AB (publ)

iZafe Group är ett renodlat Life-Science företag som leder utvecklingen av digital läkemedelsdispensering. Bolaget bedriver forskning, utveckling och marknadsföring av digitala medicinska lösningar och tjänster för tryggare läkemedelshantering i hemmet. iZafe Groups läkemedelsrobot Dosell används för att minska risken för felmedicinering i hemmet, avlasta den offentliga vården, öka livskvaliteten för patienten samt skapa en tryggare miljö för anhöriga. Kunderna utgörs idag av offentliga och privata vårdgivare i Sverige, Norden och globalt. iZafe Group säljer primärt via väletablerade partners som redan besitter långa och djupa kundrelationer med de prioriterade kundgrupperna. Huvudkontoret ligger i Stockholm.

Bolaget är noterat på NASDAQ First North Premier Growth Market. FNCA Sweden AB är bolagets Certified Adviser. Telefon: +46 (0) 8 528 00 399. E-post: . Ytterligare information finns på www.izafe.se/investor-relations/.

Bifogade filer

Sex av tio sjuksköterskor varnar för undermålig läkemedelshantering
Ivo Tillsyn Av Medicinsk Vard Och Behandling Vid Sarskilda Boenden For Aldre

Sex av tio sjuksköterskor varnar för undermålig läkemedelshantering
Ivo Tillsyn Av Medicinsk Vard Och Behandling Vid Sarskilda Boenden For Aldre

iZafe Group Q2 Interim Report, April-June 2022

iZafe Group AB (publ.) – presents today, August 26, its report for the second quarter.

Summary of financial performance

  • Net sales for the quarter amounted to SEK 84 (12) thousand. The quarter's net sales consist of revenues related to the sale of the Dosell digital pharmaceutical robot.
  • Operating profit for the quarter amounted to SEK -5,184 (-7,962) thousand.
  • Profit after financial items for the quarter amounted to -5,233 (-8,258) TSEK.
  • Cash flow for the period amounted to SEK -7,155 (-5,400) thousand.
  • Earnings per share for the quarter before / after dilution amounted to SEK -0,1 (-0,2).
  • Equity per share at the end of the period amounted to SEK 0,4 (0,4).
  • The equity/assets ratio at the end of the period was 81.8 (39.5) percent.

Significant events in the quarter

  • The company has launched an updated version of Dosell that includes several new improvements and features that enhance both the user experience and reliability.
  • During the month of June, the company has delivered a large batch to Apoteket AB, which has had a high demand for the company's products and has sold out of its stock.

Significant events after the end of the quarter

  • iZafe signs a Letter of Intent to acquire Pilloxa AB. Pilloxa has developed a technical platform for improved adherence that pharmaceutical companies use to design digital patient support. The purchase price will be paid in 70,874,308 newly issued iZafe shares with an indicative value of approximately 30 million SEK.

COMMENTS FROM THE CEO
Our vision is to ensure health through better adherence and in the last quarter we have taken an even bigger step through our updated vision and strategy presented in May.
 
During the second quarter, we focused on consumer advertising, which continues to deliver good results and improved Dosell's performance. At the same time, we are seeing increased interest among municipalities in both pharmaceutical robots and the data they can bring to medication management. After the end of the quarter, we announced a letter of intent to acquire Pilloxa AB.
 
The acquisition of Pilloxa creates a unique position in digital health
With the acquisition of Pilloxa, we have the opportunity to create a more comprehensive offering that meets the different needs of consumers, from independent medication management to the choice of a smart connected pillbox or a fully automated medication robot.
 
The acquisition of Pilloxa also gives us access to additional sales channels as we complement each other very well. Pilloxa has had pharmaceutical companies as its primary customer group and has developed a unique SaaS solution as well as support for the conduct of clinical studies. Immediately after the acquisition, we will start the journey towards making Pilloxa's solution more commercially viable in our existing sales channels.
 
Pilloxa's employees and the expertise they bring, are an important part of the acquisition. They come in with the right kind of knowledge and the experience we need to create a company that takes the position of being the leader in the market to ensure adherence to medication and ultimately, to demonstrate the health benefits of it. We are working to optimize our organization to cut costs and prepare for a future merge.
 
The company is continuing discussions with investors, who are keen to see more acquisitions and organic growth in a market that is largely untapped. Following our communication regarding the acquisition of Pilloxa, interest has increased further – which is positive for future funding of the company in addition to the warrant program TO10B which, depending on the stock price, will provide a better capital contribution.
 
B2C – continual increased sales and the potential outside Sweden
In recent months, we have invested in television advertising to spread awareness of Dosell. As a result, we now sell around 100 units a month via the Apoteket website and the consumer version of Dosell accounts for around 90% of all dispensations today. This is a very good start for a brand-new type of product and service, but not enough and hence need to find more ways to get higher volumes out.
 
Our investment here in Sweden with the consumer version of Dosell has been crucial in creating the experience and knowledge needed to export the solution to other countries and markets. In all dialogues with potential partners, there has also been interest in our vision's future solutions, which we will now be able to sell and distribute much more quickly in connection with the acquisition of Pilloxa.
 
However, the concept in Italy continues with delays due to production and software changes. The Italian market has great potential where we see great advantages in the customer being able to have their medicines packaged in sachet bags directly by the local pharmacy together with their Dosell. In the Swedish market this is a challenge where we see long lead times to get their medicines in sachet bags if they do not already use it when they have bought their Dosell. Therefore, we see great potential in the Italian concept, which is also applicable to more markets in Europe.
 
B2B – interest in medication data
We see a clear trend that more municipalities are starting to demand pharmaceutical robots, with many tenders just coming out in both Sweden and Norway.
 
We have also noticed strong demand from welfare platforms that want to get data on medication. With the acquisition of Pilloxa, this becomes a complete solution for welfare platforms as we can provide even more data around medication adherence.
 
Continuous improvement
We are constantly working to improve Dosell's performance. As we communicated in the spring, we had production challenges and a software release that included improvements necessary for our partners to deploy their Dosell in the field. These elements were completed too late into the summer holidays and as a result our partners are now able to go live after the summer months.
 
We have an exciting and intense period ahead of us. Our many partners and customers will start up the use of Dosell, we will finalize all the elements around the acquisition and ensure to develop an attractive joint future offering.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

This information is information that iZafe Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-08-26 08:30 CEST.

Attachments

Q2 Interim Report IZafe Group 2022

Q2 Interim Report IZafe Group 2022

iZafe Group invites shareholders and other stakeholders to a Q&A session in connection with the publication of the second quarter report

iZafe Group AB (publ) – announces that in connection with the interim report for the second quarter of 2022, which will be published at 08:30 CET on August 26, 2022, shareholders, media, and other stakeholders will be given the opportunity to ask questions to the company.

The questions will be answered by CEO Anders Segerström and published on iZafe Group's investor page on September 2, 2022, under the heading financial reports, investor questions.
Please send your questions to before 10:00 CET (10 a.m.) on August 30, 2022.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

iZafe Group invites shareholders and other stakeholders to a Q&A session in connection with the publication of the second quarter report

iZafe Group invites shareholders and other stakeholders to a Q&A session in connection with the publication of the second quarter report

Live interview regarding the acquisition of Pilloxa

iZafe Group (publ.) hereby invites you to a live interview with Pilloxa's CEO Helena Rönnqvist and iZafe Group's CEO Anders Segerström on Wednesday, August 24 at 2 p.m. due to the fact that iZafe has signed a letter of intent with Pilloxa to acquire 100 percent of the shares in Pilloxa.

Read the full news here.

During the interview, all shareholders and stakeholders will get a more in-depth understanding of the rationale behind the acquisition, about Pilloxa as a company and what the acquisition means for the future iZafe Group.

Links to the interview can be found here
LinkedIn
Facebook

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

Live interview regarding the acquisition of Pilloxa

Live interview regarding the acquisition of Pilloxa

iZafe signs a Letter of Intent to acquire Pilloxa AB

iZafe Group AB (publ) ("iZafe" or the "Company") has signed a Letter of Intent with Pilloxa AB ("Pilloxa") regarding the acquisition of 100 percent of the shares in Pilloxa (the "Acquisition"). Pilloxa has developed a technical platform for better compliance that pharmaceutical companies use to design digital patient support. A new company within digital health is created through the acquisition that is well positioned to become a leading company within better and more secure use of pharmaceuticals.

The Letter of Intent concerns 100 percent of the shares in Pilloxa. The purchase price is paid at 100 percent of 70,874,308 newly issued iZafe shares at an indicative value of approximately SEK 30 million. The indicative value of Pilloxa may be adjusted upwards or downwards depending on the development of the share price on the day of entry. Given that the indicative offer is accepted, the shareholders in Pilloxa will own 50 percent of the shares in the joint company after the takeover, which is expected to take place during Q3 2022. The acquisition is subject to approval at an extraordinary general meeting of iZafe Group AB. More information about the extraordinary general meeting will be published in a separate press release.
 
– For a long time, we have developed the drug dispensing robot Dosell and established a network of partners
and collaborations that see great value in medication data to enable proactive care. Through the acquisition of Pilloxa, we are now taking the next step towards our vision of improved health with better compliance, whose digital platform can be leveraged and integrated directly into our existing products and offerings. It creates an attractive and complete offer, access to a larger customer base and additional sales channels. Together we are creating something unique within the framework of digital health, says Anders Segerström, CEO of iZafe.
 
– With Pilloxa's digital offering and long-term collaboration with the pharmaceutical industry and together with iZafe, we are able to offer a comprehensive solution for our customers; patients, healthcare professionals and the pharmaceutical industry. Pilloxa's promise to our customers today is a complete digital solution for patient support within one month of the initiation meeting. We are therefore used to rapid integrations and will immediately begin to work on offering a joint digital solution, says Helena Rönnqvist, CEO of Pilloxa.
 
Incorrect or inadequate medication is a major and expensive problem for both the individual and drug development companies and costs society significant sums. Offering patients support to take their medication correctly has been shown to be an effective way to achieve better medical outcomes. Both iZafe and Pilloxa today offer solutions that support patients in safe medical treatment. The merger means a broader and attractive offer to both healthcare providers, the pharmaceutical industry and consumers, broadens the customer base and is expected to contribute to accelerated market penetration through clear sales and margin synergies.
    
About Pilloxa
Pilloxa is a Swedish company that develops apps for patients to support them in adherence to their treatment and to connect patients, healthcare providers and the pharmaceutical industry. The company provides a SaaS platform where pharmaceutical companies and other customers can design digital patient support quickly, securely and at a low cost. Connected aids such as Pilloxa's self-developed smart medication dose can also be connected to the service to support patients in taking the correct medication. Customers and partners of Pilloxa include pharmaceutical companies such as Bayer Nordics and the Nordic office of Chiesi Global Rare Diseases, university hospitals such as the University Hospital in Oslo and universities such as the University of Gothenburg.
 
    
Advisor
Mangold Fondkommission AB is the financial advisor to iZafe in connection with the Acquisition.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

This information is information that iZafe Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-08-18 08:30 CEST.

Attachments

iZafe signs a Letter of Intent to acquire Pilloxa AB

iZafe signs a Letter of Intent to acquire Pilloxa AB

Continued high demand for the consumer version of Dosell

Stockholm – iZafe Group (publ.) Announces today that it has delivered an additional 100 Dosell units to Apoteket AB in addition to deliveries of 130 units earlier in June. A total of 230 units were now delivered during the month of June to Apoteket AB.

– The great demand is a proof that more and more people want to use new digital technology in their daily lives to free up time and ensure compliance in their or their relatives medication. It also shows that Apoteket's online store is a good way to reach those who want safer drug handling at home, says Anders Segerström, CEO of iZafe Group AB.
 
This summer, iZafe will release a new feature in the Dosell app that makes it even easier to follow up on your own or relatives medication.
 
– This new function makes it even easier to follow your own or your relatives medication. We also know that the opportunity to test Dosell contributes to the experience of what a difference Dosell really makes. Therefore, we will in the TV commercial highlight that you get the opportunity to send Dosell back within 30 days if you are not satisfied with the product. This is so that even more people will dare to take the step of testing new digital technology that frees up time and ensures compliance in their or their relatives medication, says Anders Segerström, CEO of iZafe Group AB.
 
– The consumer version of Dosell is unique and currently Europe's only pharmaceutical robot for the private market based on dose bags. This has attracted the attention of several players where dialogues are now being conducted to launch Dosell for consumers in several markets in Europe, says Anders Segerström, CEO of iZafe Group AB.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Image Attachments

Dosell Ny Funktion

Attachments

Continued high demand for the consumer version of Dosell

Continued high demand for the consumer version of Dosell
Dosell Ny Funktion

New delivery of Dosell to Apoteket AB

iZafe Group (publ.) hereby announces that a large amount of Dosell will be delivered from the factory to Apoteket AB today, after being out of stock for about 6 weeks.

“We are pleased to be able to refill Apoteket AB's warehouse after Dosell has been sold out for a period. As more and more people use Dosell, we work focused on securing production and improving its functionality.

The latest update contained a bug that caused Dosell to restart from time to time. This has led to delays in deliveries, both of the consumer version and the corporate version, which has affected the municipalities' planned project starts of Dosell. As we approach the holiday season, most municipalities have chosen to postpone the introduction until after the summer.

The new, updated version of Dosell includes several new improvements and features that will improve both the user experience and reliability. Consumers using Dosell will not be affected as the new software is updated over the cloud.” Says Anders Segerström, CEO of iZafe Group AB.

About Dosell
The pharmaceutical robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
It is estimated that 3,000 Swedes die each year from medication-related injuries and 6–16 percent of hospital admissions are medication-related, according to a compilation from the Swedish National Board of Health and Welfare.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing medication-related injuries.
Read more at www.dosell.se

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

New delivery of Dosell to Apoteket AB

New delivery of Dosell to Apoteket AB

Business unit manager at Dosell buys shares in iZafe Group AB

Dosell's business unit manager, Henrik Windahl, has acquired 319,841 shares in the company.

Henrik Windahl, who recently began his employment as department manager for Dosell in iZafe Group's wholly owned subsidiary Dosell AB, has today acquired 319,941 Series B shares in the company to a value of SEK 163,534 (SEK 0.51 / pc).

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

Business unit manager at Dosell buys shares in iZafe Group AB

Business unit manager at Dosell buys shares in iZafe Group AB

iZafe Group presenterar på Aktiespararnas Småbolagsdagar

iZafe Groups VD Anders Segerström kommer att presentera bolaget på Aktiespararnas evenemang Småbolagsdagarna den 13 juni. Presentationen kommer att fokusera på bolagets nyligen uppdaterade vision och strategi samt framtidsutsikter, i både närtid och på längre sikt.

13 juni klockan 08.00 medverkar iZafe Group på Aktiespararnas evenemang Småbolagsdagarna. Verkställande direktör Anders Segerström kommer att presentera iZafe och svara på dina frågor om bolaget.
iZafe inbjuder dig som journalist, analytiker och aktieägare att ta del av presentationen live på webben, via www.aktiespararna.se/tv/live. Evenemanget är öppet för alla och kräver inget medlemskap hos Aktiespararna. Ingen anmälan krävs för att följa evenemanget digitalt.

Passa på att ställa dina frågor till Anders Segerström, genom att skicka ett sms till 079-347 98 45 eller maila till . Dina frågor kommer att förmedlas av Aktiespararnas moderator i samband med frågestunden efter presentationen. Du kan skicka in dina frågor redan nu eller i samband med presentationen.
 
INFORMATION
När: måndagen den 13 juni klockan 08.00
Livesändning: www.aktiespararna.se/tv/live
Se på plats: Hotel Birger Jarl på Tulegatan 8

Kontakter

Anders Segerström, Verkställande Direktör
Mail:
Mobilnummer: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-post:
www.izafe.se/investor-relations/

Om iZafe Group AB (publ)

iZafe Group är ett renodlat Life-Science företag som leder utvecklingen av digital läkemedelsdispensering. Bolaget bedriver forskning, utveckling och marknadsföring av digitala medicinska lösningar och tjänster för tryggare läkemedelshantering i hemmet. iZafe Groups läkemedelsrobot Dosell används för att minska risken för felmedicinering i hemmet, avlasta den offentliga vården, öka livskvaliteten för patienten samt skapa en tryggare miljö för anhöriga. Kunderna utgörs idag av offentliga och privata vårdgivare i Sverige, Norden och globalt. iZafe Group säljer primärt via väletablerade partners som redan besitter långa och djupa kundrelationer med de prioriterade kundgrupperna. Huvudkontoret ligger i Stockholm.

Bolaget är noterat på NASDAQ First North Premier Growth Market. FNCA Sweden AB är bolagets Certified Adviser. Telefon: +46 (0) 8 528 00 399. E-post: . Ytterligare information finns på www.izafe.se/investor-relations/.

Bifogade filer

iZafe Group presenterar på Aktiespararnas Småbolagsdagar

iZafe Group presenterar på Aktiespararnas Småbolagsdagar

iZafe Group updates its vision and strategy

The Board and management have for a long period developed iZafe Group's vision and strategy. We are now presenting it to shareholders and stakeholders to create an understanding of where iZafe Group is heading as a company.

Today, the company offers a product, Dosell, which is based on ensuring the right medicine at the right time via sachets. However, the importance of good adherence applies to more than those who receive medication via sachets. By broadening our offer from manual medicine management in the mobile app to a comprehensive offer that automates the entire flow with Dosell, iZafe Group becomes the company that helps everyone to take the right medicine at the right time.
 
Our new vision is therefore "health thanks to good adherence."
 
To achieve this, we will develop a comprehensive range of digital services and products that ensure that the right medicine is taken at the right time with the goal of being able to clearly show the health effects of adherence combined with values from other sensors:

  • Our app is the basis for all solutions that can be used together with Dosell, other devices or as a standalone service and should remind and ensure adherence regardless of whether the medicines are packaged in sachets, pill jars, injection, tablet, or in liquid form. It shall also keep statistics and possibly alert in the event of no medication. Alarms can reach the user as well as relatives and / or care staff.
  • Sorting in a container for medicines where we offer a smartly connected version that with the help of our app helps with sorting, reminders, statistics and alarms to selected people in case of missed medication.
  • Medicine in a sachet where we, with the help of Dosell, automate all aspects of the medication.

In this way, we get access to a large amount of data that will help us understand our customers, know when to offer the user products to ensure adherence, create opportunities for new collaborations and a basis for doctors regarding future care interventions or changes in medication.
 
Adherence data is also an important basis for pharmaceutical companies and other stakeholders conducting clinical studies. Therefore, these stakeholders are also a potential stakeholder for iZafe Group.
 
“We are now entering a new phase of our journey towards becoming a market leader to improve adherence and thus health. We must ensure that everyone who medicates has the best conditions to take the right medicine at the right time through smart, digital and modern solutions. During the rest of 2022, we will be able to see several interesting updates in our company to ensure that this further development goes according to plan. We look forward to being able to communicate them in the near future.” says Joachim Källsholm, Chairman of the Board of iZafe Group AB.
 
Linked to the new strategy, several changes are now being implemented within the organization. With the new direction that the company is taking, the board has agreed together with vice president and commercial director Tobias Johansson to go their separate ways.
 
iZafe Group has chosen to recruit Henrik Windahl as Business Unit Manager, who will start on May 30. Henrik's background and extensive experience in partner sales and business development will help to take the company's sales of Dosell to the levels needed to be able to take the next step in iZafe Group's development and success both nationally and internationally.
 
Read iZafe Group's new company narrative here.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

iZafe Group updates its vision and strategy

iZafe Group updates its vision and strategy
Webbdesign av Comlog Webbyrå Stockholm